Clinical relevance and biomarker search of erlotinib against chemotherapy-treated recurrent non-small cell lung cancer
- Conditions
- Chemotherapy-treated recurrent non-small cell lung cancer
- Registration Number
- JPRN-UMIN000002811
- Lead Sponsor
- Department of Respirology/Division of Clinical Oncology, Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 46
Not provided
Patients with at least one of the following conditions are ineligible 1) Patients with idiopathic pulmonary fibrosis, other interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug induced pulmonary damage 2) Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage 3) Patients with infection requiring iv administration of antibiotics and/or antifungal agents 4) Patients unable to be treated with PO drugs 5) Clinically significant eye diseases such as severe dry eye, keratoconjunctivitis 6) Pregnancy, breast feeding and suspected pregnancy 7) Symptomatic brain metastasis 8) Active synchronous malignancies 9) Uncontrolled diabetes mellitus 10) Other clinically significant complications 11) Other conditions inadequate for this research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate at week 8.
- Secondary Outcome Measures
Name Time Method Response rate, waterfall plot analysis, progression free survival time, overall survival time, safety, biomarker analysis, detection of EGFR mutation in blood sample